Frontiers in immunology · 2026
Poly-IgA immune complex as a monitoring biomarker of response to telitacicept in IgA nephropathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fu Rao, Gao Jingyang, Zhang Yu, He Zhe, Du Xuanyi
Аннотация
BACKGROUND: Immunoglobulin A nephropathy (IgAN) is a common immune-mediated kidney disease. Its pathogenesis involves dysregulated B cell activation, excessive production of galactose-deficient immunoglobulin A1 (Gd-IgA1), and formation of IgA immune complex, which collectively drive glomerular injury. Telitacicept, a fusion protein that blocks B cell activation pathways, may counteract these mechanisms, but observational data and reliable biomarkers of therapeutic response remain limited.
OBJECTIVE: This study aimed to evaluate the clinical efficacy and safety of telitacicept and to determine whether changes in circulating B cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), and Poly-IgA immune complex (Poly-IgA) reflect treatment response.
METHODS: In this single-center retrospective cohort study, 38 adult patients with IgAN received telitacicept combined with low-dose glucocorticoids for up to 9 months. Clinical outcomes, renal function, and safety events were monitored longitudinally, and serum biomarkers were analyzed to assess associations with remission.
RESULTS: Telitacicept treatment resulted in a substantial and sustained reduction in proteinuria while maintaining stable renal function, with over half of patients achieving complete or partial remission at 3 months. All three biomarkers reduced with treatment, and Poly-IgA showed the strongest correlation with clinical remission and the best ability to distinguish remission from non-remission.
CONCLUSION: Telitacicept is an effective and well tolerated drug in the treatment of IgAN, with immunomodulatory effects consistent with suppression of pathogenic B cell activity. The lower level of Poly-IgA during treatment is significantly associated with clinical remission.It may serve as a promising biomarker for monitoring treatment response in the future, supporting its potential use in guiding individualized therapy for patients with IgAN.
OBJECTIVE: This study aimed to evaluate the clinical efficacy and safety of telitacicept and to determine whether changes in circulating B cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), and Poly-IgA immune complex (Poly-IgA) reflect treatment response.
METHODS: In this single-center retrospective cohort study, 38 adult patients with IgAN received telitacicept combined with low-dose glucocorticoids for up to 9 months. Clinical outcomes, renal function, and safety events were monitored longitudinally, and serum biomarkers were analyzed to assess associations with remission.
RESULTS: Telitacicept treatment resulted in a substantial and sustained reduction in proteinuria while maintaining stable renal function, with over half of patients achieving complete or partial remission at 3 months. All three biomarkers reduced with treatment, and Poly-IgA showed the strongest correlation with clinical remission and the best ability to distinguish remission from non-remission.
CONCLUSION: Telitacicept is an effective and well tolerated drug in the treatment of IgAN, with immunomodulatory effects consistent with suppression of pathogenic B cell activity. The lower level of Poly-IgA during treatment is significantly associated with clinical remission.It may serve as a promising biomarker for monitoring treatment response in the future, supporting its potential use in guiding individualized therapy for patients with IgAN.